In case 1, two samples of the tumor tissue were also analyzed for activity of cell signaling pathways using phosphoprotein arrays for detection of RTKs, MAPKs, serine/threonine kinases, and other signaling protein as specified above: tumor tissue sample after the first line of treatment (Figure 2: case 1a) and second sample taken during the treatment of relapsed disease (Figure 2: case 1b). The gene discussed is MARK2; the disease is neoplasm.